Výsledky vyhledávání - "Carrie Wagner"

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

Autor: Robert Gordon, Brad H. Rovin, Benjamin Hsu, Cynthia Aranow, Ronald F van Vollenhoven, Yanli Zhuang, Stanley M. Belkowski, Carrie Wagner

Publikováno v: Arthritis & Rheumatology. 68:2174-2183

Objective To assess the efficacy and safety of sirukumab, an anti-interleukin-6 monoclonal antibody, for the treatment of patients with active lupus nephritis (LN). Methods Patients with class III or class IV LN (as determined by renal biopsy within

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7539873c40c38bd14d4fb5fb1bee4314
https://doi.org/10.1002/art.39722

Zobrazit plný text záznamu

FRI0339 Sledai-2k responder index-50 is effective in demonstrating partial response in a phase 2, randomised placebo-controlled study of ustekinumab in patients with active systemic lupus erythematosus

Autor: Shawn Rose, Dafna D. Gladman, M. B. Urowitz, B. Hsu, Carrie Wagner, R. Gordon, Marc Chevrier, B. Zhou, Zahi Touma

Publikováno v: FRIDAY, 15 JUNE 2018.

Background Ustekinumab (UST), a monoclonal antibody that targets shared p40 subunit of cytokines IL-12 and IL-23, is being investigated in pts w/active systemic lupus erythematosus(SLE). While traditional SLE Disease Activity Index 2000(SLEDAI-2K)sco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c73f30a726c7a37def1d0a907ad500b3
https://doi.org/10.1136/annrheumdis-2018-eular.4877

Zobrazit plný text záznamu

FRI0303 Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study

Autor: M. Triebel, R. van Vollenhoven, Bevra H. Hahn, R. Gordon, George C. Tsokos, B. Hsu, Carrie Wagner, Peter E. Lipsky, Marc Chevrier, Shawn Rose

Publikováno v: FRIDAY, 15 JUNE 2018.

Background IL12 and IL23 have been linked to SLE pathogenesis. Objectives The anti-IL12/23 monoclonal antibody ustekinumab (UST) was evaluated in pts with active SLE. Methods We conducted a Ph2, PBO-controlled study in 102 pts with active SLE. Pts we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::49eb117e829887dbf89da9c7e35deb84
https://doi.org/10.1136/annrheumdis-2018-eular.1734

Zobrazit plný text záznamu

S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study

Autor: Bevra H. Hahn, B. Hsu, Peter E. Lipsky, Marc Chevrier, M. Triebel, R. Gordon, Carrie Wagner, Shawn Rose, George C. Tsokos, R. van Vollenhoven

Publikováno v: S7a – New therapeutic candidates.

Purpose IL12 and IL23 pathway have been linked to SLE pathogenesis. Anti-IL12/23 monoclonal antibody ustekinumab (UST) previously approved for psoriasis, psoriatic arthritis, and Crohn’s diseasewas evaluated in pts with active SLE. Methods A Ph2, P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::41893c2d3c6433ccd86a3981da960750
https://doi.org/10.1136/lupus-2018-abstract.45

Zobrazit plný text záznamu

Evaluation of Serum Biomarkers Associated with Radiographic Progression in Methotrexate-naive Rheumatoid Arthritis Patients Treated with Methotrexate or Golimumab

Autor: Roy Fleischmann, Michael Mack, Dion Chen, Paul Emery, Elizabeth C. Hsia, Carrie Wagner, Hongtao Fan

Publikováno v: The Journal of Rheumatology. 40:590-598

Objective.To evaluate associations between biomarkers and radiographic progression in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) treated with MTX or golimumab, a tumor necrosis factor inhibitor (with or without MTX).Methods.Seru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb329cd4ad90015fee2974ca9b23fb23
https://doi.org/10.3899/jrheum.120889

Zobrazit plný text záznamu

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

Autor: A. Beutler, Frederick T. Murphy, Kim A. Papp, Philip J. Mease, Sudha Visvanathan, Dafna D. Gladman, Juan J. Gomez-Reino, Michael Mack, Gerald G. Krueger, Carrie Wagner, Iain B. McInnes, Michael Elashoff, Arthur Kavanaugh

Publikováno v: Annals of the Rheumatic Diseases

Objective To determine serum biomarker associations with clinical response to golimumab treatment in patients with psoriatic arthritis (PsA). Methods GO–REVEAL was a randomised, placebo-controlled study of golimumab in patients with active PsA. Sam

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::196d70b7a6eeee115ea30b478c5700e3
http://europepmc.org/articles/PMC3551220

Zobrazit plný text záznamu

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

Autor: Stephen B. Hall, Zhenhua Xu, Peter Nash, Elizabeth C. Hsia, Sudha Visvanathan, Mahboob Rahman, Jonathan Kay, J. Han, Bhaskar Dasgupta, Carrie Wagner, Patrick Durez, Eric L. Matteson

Publikováno v: Arthritis & Rheumatism. 58:964-975

Objective. To assess the efficacy, safety, and pharmacology of subcutaneous administration of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX). Methods. Patients were randomly assigned in a double-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96bdc65d70b593000d7f13794eddebab
https://doi.org/10.1002/art.23383

Zobrazit plný text záznamu

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

Autor: T. Gathany, Carrie Wagner, J C Marini, Jürgen Braun, D. van der Heijde, David Baker, Sudha Visvanathan, J. Han

Publikováno v: Annals of the Rheumatic Diseases

Objective:To evaluate the relationship between biomarker levels and disease activity and the spinal inflammation detected by magnetic resonance imaging (MRI) in patients with ankylosing spondylitis (AS).Methods:Patients with AS were randomly assigned

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1218668844dc43b431907fb3540f7a
http://europepmc.org/articles/PMC2564765

Zobrazit plný text záznamu

Double-blinded infliximab dose escalation in patients with rheumatoid arthritis

Autor: Daniel Baker, David E. Yocum, Rene Westhovens, Carrie Wagner, Piet Geusens, Mahboob Rahman, Alberto Berman, J. Han, Ingrid Strusberg

Publikováno v: Annals of the Rheumatic Diseases. 66:1233-1238

Objective: To determine the efficacy, safety and pharmacokinetics of infliximab dose escalation in patients with rheumatoid arthritis (RA) who had an inadequate response to 3 mg/kg infliximab treatment or whose disease flared after initially respondi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed579e2aea9d14dc6b8001b975a4cf7
https://doi.org/10.1136/ard.2006.065995

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání